Brief: Bavarian Nordic Phase 3 Study For COVID-19 Booster Vaccine Candidate Met Primary Objective

ExpreS2ion Biotech Holding AB

27/06/2023 14:01

(Adds metadata to expand audience. No changes to text.)
       June 27 (Reuters) - Bavarian Nordic A/S  BAVA.CO :
    * REPORTS PHASE 3 TOPLINE RESULTS FOR ITS COVID-19 BOOSTER VACCINE CANDIDATE
    * BOOSTER STUDY SUCCESSFULLY MET ITS PRIMARY OBJECTIVE, DEMONSTRATING NON-INFERIORITY TO
MRNA-VACCINE
    * REGULATORY PATHWAY WILL DEPEND UPON OUTCOME OF SECONDARY ENDPOINTS, REPORTING IN Q3 OF
2023
    * ABNCOV2 WAS NON-INFERIOR TO COMIRNATY® IN TERMS OF NEUTRALIZING ANTIBODIES AGAINST
SARS-COV-2
    * RESULTS FROM SECOND PART OF STUDY WILL BECOME AVAILABLE IN Q3 OF 2023.
    * SECOND PART OF STUDY, WHICH IS EVALUATING SAFETY AND TOLERABILITY OF A SINGLE 100 ΜG DOSE
OF
ABNCOV2, HAS ENROLLED 3,583 PARTICIPANTS
    * IS LIKELY INSUFFICIENT TO SUPPORT A PRODUCT APPROVAL ON ITS OWN
    * SECONDARY OBJECTIVES WILL BE IMPORTANT TO UNDERSTAND CURRENT EFFECTIVENESS OF ABNCOV2.
    * THESE RESULTS ARE ANTICIPATED IN Q3 OF 2023.
    * PHASE 3 RESULTS FOR OUR COVID-19 BOOSTER VACCINE CANDIDATE CONFIRMED VLP PLATFORM AS A
VIABLE
FUTURE PANDEMIC VACCINE PLATFORM

Source text for Eikon:  ID:nGNE7fjND5 
Further company coverage:  BAVA.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))